Introduction
Cardiovascular (CV) disease and diabetes are major global health burdens, accounting for more than 20 million deaths annually.
1,2
Coronary artery disease is a major component of CV disease, responsible for nearly half of all CV deaths. 1 In the general population, diabetes is an important risk factor for the development of coronary artery disease and myocardial infarction (MI). 3, 4 Indeed, the risk for CV mortality is two-fold higher in patients with diabetes. 5 Furthermore, patients with diabetes have an even more strongly elevated risk for onset of heart failure (HF). 6 -9 Left ventricular dysfunction (LVD) is the single strongest predictor for mortality following acute MI. Recognizing the impact of comorbidities and the clinical importance of CV complications, a novel effort was made to create the High-Risk MI Database consisting of individual patient data from 28 771 patients with MI and clinical signs of HF or LVD from four recent large multi-centre randomized clinical trials with similar demographics.
10
While the risk contribution of diabetes to CV morbidity and mortality is well known, it is less well understood to which degree a history of diabetes is an independent risk factor for adverse outcomes when high-risk CV complications (including MI, LVD, or clinical signs of HF) are already present. Although previous studies have suggested important risk associations, 11 -13 these analyses were conducted in a smaller number of patients 11, 12 or the patients could not benefit from the full range of modern post-MI management. 13 In contrast, the large High-Risk MI Database included patients from four trials conducted after 2000 and the patients received modern post-MI management including ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists, anti-hypertensive treatment, lipid-lowering agents, antiplatelet therapy, and revascularization.
In response, we seek to examine the magnitude of the remaining risk of diabetes for adjudicated outcomes in the presence of established serious CV morbidity in current populations taking advantage of the unique attributes of the common database.
Methods

Study design, setting and participants
The construction of the High-Risk MI Database was led by the Scientific Committee (see Appendix for Committee members), and the background has been detailed elsewhere. 10 Briefly, the creation of the database was a novel endeavour entailing the first ever large-scale merging of individual patient data from large randomized clinical trials. With a combined total of 28 771 patients, this database represents one of the largest available study populations of high-risk patients following MI. Each of the four individual trials examined the impact of pharmacological interventions in patients following MI with clinical signs of HF or LVD. 10 There were a high number of events, in total 1739 deaths and 8275 hospitalizations. Importantly, this population differs from a traditional observational population in that the individual patient data were derived from industry-initiated trials; baseline data were carefully collected with source documentation, and all end-points were adjudicated by independent committees. Additionally, all of the studies originated after 2000 and enrolled patients that received appropriate modern post-MI management. Details on the individual trial designs, randomization protocols, determination of sample sizes, procedures, and the respective inclusion criteria have been reported previously. 14 -17
The individual trials were: Valsartan in Acute Myocardial Infarction Trial (VALIANT), 16 Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Trial (EPHESUS), 17 with acute MI complicated by signs of HF or LVD. The OPTIMAAL trial tested the effect of losartan vs. captopril in 5447 patients with acute MI and signs or symptoms of HF. The CAPRICORN trial studied the effect of carvedilol vs. placebo on top on standard therapy in 1959 patients with MI and LVD. The prevalence of diabetes in the individual studies were 3877 (26%), 2142 (32%), 940 (17%), and 427 (22%), respectively. All the studies in the database recorded self-reported diabetes status at patient randomization as a binary. Only EPHESUS included baseline categorization (check box question) into type 1 or 2 diabetes mellitus. Furthermore, OPTIMAAL did not record the presence of diabetes in a binary format and therefore specific search terms had to be used instead during data extraction. Due to this, some cases of diabetes may have been missed during extraction, which may in turn explain the lower prevalence of diabetes in OPTIMAAL as compared to the other studies.
In order to protect the interests of the original sponsors and to preclude meta-analyses of the pharmaceutical effects, the interventions were deleted in the process of creating the common database. To deal with this limitation and to be able to partly adjust for drug interventions we classified patients into those who received an ACE inhibitor, an ARB, or a combination of the two drugs without knowing specifically to which class patients were randomized. As shown in Table 1 , 95% of the patients in this population received an ACE inhibitor, an ARB, or a combination of the two drugs. Also in VALIANT, OPTIMAAL, and EPHESUS trials we could adjust for the use of beta-blockers, which were prescribed in about 75% of the patients. Further on, we adjusted for important CV medications, such as diuretics, digoxin, statin, and aspirin use, available in all trials. Indeed, we could not adjust for the use of eplerenone in the EPHESUS trial, but the effects of the drug intervention on population in the common database are minimized by the fact that the patients in the comparison arm in the EPHESUS trial also received placebo.
Outcomes
Major clinical outcomes were Centrally adjudicated by end-point Committees. Conventional criteria were used by the Committees in their evaluations and the definitions of these have been published in the respective studies. In this report the following outcomes are analysed: all-cause death, CV death (sudden death, fatal re-infarction, death from stroke, and death from worsening HF), non-CV death, all-cause hospitalization, CV hospitalizations (HF hospitalizations, recurrent MI, and stroke). Several composite outcomes are also analysed: all-cause death or first all-cause hospitalization, CV death or first CV hospitalization, HF death or HF hospitalization, and CV death or non-fatal MI or non-fatal stroke.
Statistical analysis
At baseline, continuous variables were described as means ± standard deviation, and categorical variables as frequencies (percentages). The difference in clinical variables, medical history, and medication between patients with and without diabetes was compared by using a t-test or a 2 test, as required.
Cox proportional hazard models were fitted to assess the association between baseline history of diabetes and clinical outcomes. We checked the log-linearity of the continuous variables and the Cox proportionality assumptions of all variables by generating one dummy variable per quintile of each variable, entering these in the Cox model, and plotting the resulting Cox estimators against the mean values of the quintiles. Assumptions of risk proportionality were assessed statistically by testing the cofactor × time interaction and visually by plotting the log [−log(survival)] curves. All variables significantly different at baseline (P < 0.05) were included in the multivariate Cox analysis.
The following variables were included in the final multivariate model: age, gender, race, smoking status, body mass index (BMI), systolic blood pressure (SBP), heart rate, estimated glomerular filtration rate (eGFR), Killip class, history of angina, hypertension, dyslipidaemia, renal insufficiency, peripheral vascular disease, atrial fibrillation, cerebrovascular accident, previous HF hospitalization, previous MI, history of percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG), and concomitant medication with beta-blockers, diuretics, digoxin, statin, and aspirin. Cox proportional hazard models were fitted to assess the association between baseline history of diabetes and time to clinical outcome of interest. We checked for interactions between history of diabetes and all significant variables from the final models on all-cause mortality, CV mortality, and all-cause hospitalizations.
Analysis at baseline included for most variables the total sample of 28 771 patients. However, there were missing values for a few clinical variables used for adjustment; therefore, the final multivariate Cox analysis was performed in 25 575 patients. Patients with missing data were not different in major clinical and demographic characteristics from patients included in the analysis, i.e. mean age 63 years, male 73%, mean heart rate 77 b.p.m., and mean BMI 27 kg/m 2 .
All analyses were performed using SPSS version 21. Results were estimated as hazard ratios with 95% confidence interval [HR (95% CI)]. The two-tailed significance level was set at P < 0.05.
Secondary analyses
The left ventricular ejection fraction (LVEF) data registered at baseline in OPTIMAAL were not available and were therefore not included during the construction of the High-Risk MI Database. Glucose level was not available in the VALIANT trial. Thus, the main multivariate analysis did not include adjustment for these variables. In order to assess the effect of LVEF and glucose on the prognostic impact of diabetes, we performed secondary analyses in the subgroup of patients who had these variables available.
Results
Patient characteristics at baseline are presented in Table 1 . The mean age of the patients was 65 (±11) years and 70% were male. Overall, 7386 patients (26%) reported a history of diabetes. The prevalence of a history of PCI or CABG prior to randomization was similar in both groups: 1133 (21.6%) and 542 (10.3%) in those with diabetes, and 3285 (19.4%) and 977 (5.8%) in those without diabetes. Patients with a history of diabetes were older, more often men, smokers, and had a higher BMI. Furthermore, they were generally sicker, with higher heart rate and SBP, lower eGFR, lower LVEF, and more frequently with a history of comorbidities. Patients with a history of diabetes had a higher prescription rate of diuretics, statins, and digoxin, but a slightly lower prescription rate of beta-blockers and aspirin. (1525 events, 88% in patients with diabetes and 2875 events, 85% in patients without diabetes).
In univariate survival analysis, a history of diabetes was associated with a higher risk of all clinical outcomes, particularly a higher risk of death from CV causes, including MI, HF, and stroke as well as a higher risk of hospitalizations, particularly HF hospitalizations ( Table 2) . The risk of all-cause death was 60% higher in patients with vs. those without a history of diabetes (HR 1.60; CI 1.51-1.70; P < 0.001). Kaplan-Meier survival curves clearly show a higher risk of all-cause death and CV death for patients with a history of diabetes, with the two curves differentiating immediately during follow-up (Figure 1) 
Multivariate Cox analysis
After extensive adjustment, the risk of all clinical outcomes remained significantly higher in patients with a history of diabetes. The risk of all-cause death remained almost 40% higher in patients with vs. those without diabetes (HR 1.37; CI 1.28-1.46; P < 0.001) ( Table 2 ). This positive association was mostly due to a higher risk of CV death, particularly fatal re-infarction (HR 1.78; CI 1.42-2.23; P < 0.001). Patients with diabetes had also a higher risk of hospitalizations, particularly HF hospitalizations, and a higher risk of HF death or HF hospitalizations (50% higher risk) ( Table 2 ).
Secondary analyses
The data from the secondary analyses are not shown in detail. Left ventricular ejection fraction was available in 17 362 patients. After adjustment for all clinical variables and LVEF, the risk of all adverse clinical outcomes was higher in patients with diabetes, at a rate similar to that observed in the overall population, i.e. the risk of all-cause and CV mortality was approximately 40% higher in patients with vs. those without diabetes (HR 1.39; CI 1.28-1.49; P < 0.001, and HR 1.39; CI 1.28-1.52; P < 0.001). Serum glucose levels following admission were available in 11 476 patients. The risk of all-cause and CV mortality also remained higher in patients with diabetes after adjustment for this variable (HR 1.19, CI 1.05-1.35, P = 0.03; and HR 1.16, CI 1.02-1.32, P = 0.03).
Interactions
Patients with diabetes had a higher risk of adverse outcomes than patients without diabetes irrespective of demographics or concomitant medication. However, we found some significant interactions in the overall population which suggest that certain subgroups of patients with diabetes may be at particular risk. Female patients with diabetes had a higher all-cause mortality than men with diabetes (HR 1.19; CI; 1.05-1.35; P = 0.007). While the higher risk in female patients has been demonstrated before, the finding that this remains even after established MI, clinical signs of HF or LVD is novel. Patients with diabetes and lower renal function (eGFR < 75 mL/min) had a higher risk of all-cause hospitalization than those with higher renal function (eGFR ≥ 75 mL/min) (HR 0.87; CI 0.87-0.94; P < 0.001).
Discussion
While it is well-known that diabetes is associated with an increased risk for morbidity and mortality, the remaining magnitude of risk for subsequent events in the presence of established advanced CV complications has not been adequately addressed. In response, we found that high-risk MI patients with a history of diabetes have a substantially higher risk for morbidity and mortality during a mean follow-up of ∼2 years. Importantly, the risk for all-cause death was nearly 40% higher in patients with diabetes, in large part due to a higher risk for CV death-dominated by fatal re-infarction. The risk for HF hospitalization was 50% higher in patients with diabetes, and there was a similar magnitude of increased risk for HF death or HF hospitalization. Strong and highly significant associations were also demonstrated with almost all other major clinical and composite outcomes. Kaplan-Meier curves show marked and early divergence for all important end-points: all-cause death, CV death, fatal re-infarction, all-cause hospitalization, and HF hospitalization. These associations were independent of demographics and concomitant medication.
Patients with diabetes were generally older and had greater comorbidity. This may partially explain the higher occurrence of adverse events in this group. As expected, SBP was significantly higher than in those without diabetes. occurrences of peripheral artery disease, hypertension, angina, previous MI, atrial fibrillation, HF, and previous CABG were found. However, the strong and early divergence of event rates of all important end-points in the survival analysis suggests that worse outcomes in patients with diabetes are mediated through factors already established at the time of MI, including the degree of coronary artery disease, myocardial tissue health, and severity of MI. The sustained increase in risk may partially reflect the development of diabetes cardiomyopathy due to microvascular disease, autonomic dysfunction, and diastolic dysfunction. 18 -21 Furthermore, our finding that CV death and fatal re-infarction are driving the higher mortality rates among patients with diabetes is consistent with the fact that patients with diabetes are known to have more severe and diffuse underlying coronary artery disease. While the increased CV risk associated with diabetes is well recognized, the large sustained risk across all major outcomes in the presence of established CV disease represents novel data.
In our secondary analyses we were able to separately adjust for LVEF in 17 362 patients and for glucose levels at admission in 11 476 patients. By adjusting for glucose levels in the secondary analyses, we were in effect examining the effect of diabetes after controlling for glycaemic control. In both analyses we found that the risk for all-cause and CV death remained higher in patients with diabetes. These findings suggest that the deleterious effects of diabetes on outcomes following MI in high-risk patients are mediated independently of both LVD and glucose levels at admission. Previous studies have already suggested that diabetes and LVEF predict adverse outcomes independently of each other. 22 -24 An analysis on the EPHESUS population similarly showed that acute glucose levels predicted outcomes even after adjustment for diabetes. 25 Other studies have pointed to the independence of diabetes and long-term glucose levels (HbA1c) as risk factors in both patients with acute MI 26 and patients with chronic HF. 27 The combination of multiple pathophysiological pathways in the development of diabetes cardiomyopathy suggested above could explain these findings.
The current study looks at associations between diabetes and adjudicated outcomes in the High-Risk MI Database, which represents one of the largest study populations based on individual patient data (28 771 patients) with MI, and clinical signs of HF or LVD available to date. Previous studies have looked at the diabetes population in some of the studies used in constructing the High-Risk MI Database. An important study on the diabetes population in VALIANT (14 703 patients) showed that patients with diabetes had over 40% higher risk for mortality and similarly increased risk for a composite of CV outcomes. 28 Similarly, another study on the diabetes population in VALIANT stratified according to EF found that there was an increased risk for all-cause death, death or HF hospitalization, and death or recurrent MI across the spectrum EF values. 12 As expected, higher EF was associated with reduction in adverse outcomes; however, the presence of diabetes was shown to attenuate this relationship for HF-related outcomes. In contrast, a study on the EPHESUS population found a significant association only with non-fatal MI after propensity score matching, possibly because of the smaller sample size.
11 Our study strongly confirms and substantially extends the previous results. Our sample size includes patients from more sites, and is nearly twice as large as that of the previous VALIANT studies. We assess a much greater range of outcomes and find strong associations and highly significant associations with all outcomes. We describe rates of mortality similar to the above studies, but our results are stratified in greater detail according to CV death (subdivided due to sudden death, re-infarction, stroke, worsening HF) or non-CV death. Furthermore, we look at risk for hospitalization according to the underlying mechanism, such as all CV hospitalizations (subdivided due to HF, recurrent MI, or stroke). In particular, we find 50% increased risk for HF hospitalization and the composite HF death or HF hospitalization. Earlier reports have also looked at the risk-modifying properties of diabetes following MI in populations from studies that were conducted in the decades prior to the trials in the common database.
13,29 -33 However, this was a time-frame when patients did not benefit from several aspects of modern post-MI management.
This study has some major limitations. The analysis in this paper relies solely on self-reported diabetes without the use of any other objective criteria for diagnosis. Only one of the trials (EPHESUS) further classified patients into type 1 or 2 diabetes. Nevertheless, studies that have assessed the reliability of self-reported diabetes in community studies have found very high specificity in the range 84-97% and moderate/high sensitivity in the range 55-80% when compared to multiple objective reference points (including fasting glucose and HbA1c), 34 and similar results have been found when comparing to medical records. 35 Further, some patients may have developed diabetes during the trials and thus escaped baseline categorization. Type 2 diabetes subgroup analyses were not performed, as only one of the studies included in the database had check box classification of diabetes type at baseline. Categorization into type 2 diabetes based on use of oral anti-diabetic drugs was not deemed an adequate surrogate for type 2 diabetes, as studies have suggested that around 16% of patients with type 2 diabetes are on insulin-alone therapy. 36 Further, it is well documented that type 2 diabetes represents the large majority in clinical practice. The study was performed in predominantly Caucasian patients, which may limit its generalizability to other populations. Further data are needed in other racial groups.
Future research should address the potential contribution of the various pathological mechanisms that place patients with diabetes mellitus at high risk for adverse outcomes. Treatment strategies can only be optimized when the potential targets for intervention are identified.
In conclusion, a history of diabetes remains strongly predictive of adverse long-term outcomes even after serious CV complications are already established. Following MI with clinical signs of HF or LVD we found that diabetes remained strongly associated with all adjudicated major end-points and in particular HF-related outcomes such as HF hospitalization and the combined outcome HF death or HF hospitalization. Patients with diabetes mellitus therefore remain at high risk for subsequent events even after established advanced CV disease, and should be targeted for aggressive management and interventional strategies including adequate secondary prophylaxis.
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